Acquisition by Shekhat Denil Nanji of 50000 shares of MIRA Pharmaceuticals at 0.71 subject to Rule 16b-3

MIRA Stock   1.27  0.01  0.78%   
About 62% of MIRA Pharmaceuticals,'s investor base is looking to short. The analysis of overall sentiment of trading MIRA Pharmaceuticals, Common stock suggests that many investors are alarmed at this time. The current market sentiment, together with MIRA Pharmaceuticals,'s historical and current headlines, can help investors time the market. In addition, many technical investors use MIRA Pharmaceuticals, stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by MIRA Pharmaceuticals Common Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Acquisition of 50000 nonqualified stock option (right to buy) at 0.71 of MIRA Pharmaceuticals by Shekhat Denil Nanji on 18th of June 2024. This event was filed by MIRA Pharmaceuticals Common with SEC on 2024-06-18. Statement of changes in beneficial ownership - SEC Form 4

MIRA Pharmaceuticals, Fundamental Analysis

We analyze MIRA Pharmaceuticals,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MIRA Pharmaceuticals, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MIRA Pharmaceuticals, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Institutions

Shares Owned By Institutions Comparative Analysis

MIRA Pharmaceuticals, is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

MIRA Pharmaceuticals, Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MIRA Pharmaceuticals, stock to make a market-neutral strategy. Peer analysis of MIRA Pharmaceuticals, could also be used in its relative valuation, which is a method of valuing MIRA Pharmaceuticals, by comparing valuation metrics with similar companies.

Complementary Tools for MIRA Stock analysis

When running MIRA Pharmaceuticals,'s price analysis, check to measure MIRA Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MIRA Pharmaceuticals, is operating at the current time. Most of MIRA Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of MIRA Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MIRA Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of MIRA Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years